Dirk Pollet
Vorstandsvorsitzender bei Enzyre BV
Profil
Dirk Pollet is currently the Chief Executive Officer at Enzyre BV and also holds a Director position at Cergentis BV.
Previously, he served as the Chief Executive Officer & Director at Multiplicom NV from 2011 to 2017, Vice President-Business Development at Galapagos Genomics NV from 2000 to 2008, and Chief Business Officer at Cellectis SA from 2008 to 2011.
He holds a doctorate degree from the University of Antwerp.
Aktive Positionen von Dirk Pollet
Unternehmen | Position | Beginn |
---|---|---|
Enzyre BV
Enzyre BV Packaged SoftwareTechnology Services Enzyre BV develops biochip platform that enzymatic reactions can be measured. The company is headquartered in Nijmegen, the Netherlands. | Vorstandsvorsitzender | 30.04.2019 |
Cergentis BV
Cergentis BV Miscellaneous Commercial ServicesCommercial Services Part of Solvias AG, Cergentis BV is a Dutch genomics company that develops and commercializes TLA-based diagnostic kits for targeted complete next-generation sequencing of (trans) genes and gene editing events. The company is based in Utrecht, Netherlands. The company also provides commercial services for leading research institutes and pharmaceutical companies worldwide. The company was founded in 2012. Joris Schuurmans has been the CEO of the company since 2020. Cergentis was acquired by Solvias AG on July 12, 2022. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Dirk Pollet
Unternehmen | Position | Ende |
---|---|---|
Multiplicom NV
Multiplicom NV Medical SpecialtiesHealth Technology Multiplicom NV develops, manufactures, and commercializes molecular diagnostics solutions. It specializes in pathology laboratories, next generation sequencing, multiplex amplification of specific targets for resequencing, genetics, assay kits, clinical laboratories, and personalized medicine. The company was founded by Chris De Jonghe in 2011 and is headquartered in Niel, Belgium. | Vorstandsvorsitzender | 01.03.2017 |
CELLECTIS S.A. | Corporate Officer/Principal | 01.06.2011 |
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | Corporate Officer/Principal | 02.05.2008 |
Ausbildung von Dirk Pollet
University of Antwerp | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
CELLECTIS S.A. | Health Technology |
Private Unternehmen | 4 |
---|---|
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | Health Technology |
Multiplicom NV
Multiplicom NV Medical SpecialtiesHealth Technology Multiplicom NV develops, manufactures, and commercializes molecular diagnostics solutions. It specializes in pathology laboratories, next generation sequencing, multiplex amplification of specific targets for resequencing, genetics, assay kits, clinical laboratories, and personalized medicine. The company was founded by Chris De Jonghe in 2011 and is headquartered in Niel, Belgium. | Health Technology |
Enzyre BV
Enzyre BV Packaged SoftwareTechnology Services Enzyre BV develops biochip platform that enzymatic reactions can be measured. The company is headquartered in Nijmegen, the Netherlands. | Technology Services |
Cergentis BV
Cergentis BV Miscellaneous Commercial ServicesCommercial Services Part of Solvias AG, Cergentis BV is a Dutch genomics company that develops and commercializes TLA-based diagnostic kits for targeted complete next-generation sequencing of (trans) genes and gene editing events. The company is based in Utrecht, Netherlands. The company also provides commercial services for leading research institutes and pharmaceutical companies worldwide. The company was founded in 2012. Joris Schuurmans has been the CEO of the company since 2020. Cergentis was acquired by Solvias AG on July 12, 2022. | Commercial Services |